Atiratecan
Atiratecan (TP300) is a proagent of camptothecin analog CH0793076. Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP) -positive and -negative xenografts in mouse xenograft models[1].
Product Specifications
CAS Number
867063-97-6
Product Name Alternative
TP300
UNSPSC
12352005
Hazard Statement
H301
Target
Topoisomerase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/atiratecan.html
Solubility
10 mM in DMSO
Smiles
O=C(O[C@](C(C=C12)=C(CO3)C(N1CC(C2=N4)=C5N(CCCCC)C=NC6=C5C4=CC=C6)=O)(CC)C3=O)CN(C(CN)=O)C
Molecular Formula
C31H34N6O6
Molecular Weight
586.64
Precautions
P264-P270-P330-P405-P501
References & Citations
[1]Endo M, et al. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancerresistance protein-expressing tumor xenografts. Cancer Chemother Pharmacol. 2010 Jan;65 (2) :363-71.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
